LDL Cholesterol

The Lower the Better

Research output: Contribution to journalArticle

Abstract

High cholesterol is often a prerequisite for atherosclerotic plaque. Low-density lipoprotein cholesterol (LDL-C) is the focus of the National Cholesterol Education Program Adult Treatment Panel guidelines. LDL-C ranges from 50 to 70 mg/dL in native hunter-gatherers, healthy human neonates, free-living primates, and other wild mammals, who are notably free of atherosclerotic vascular disease. Multiple statin trials and meta-analyses support a treatment target of LDL-C levels less than 70 mg/dL, as this is associated with improved clinical outcomes and atherosclerosis regression. In fact, no threshold has yet been identified below which patients do not benefit from lowering of LDL-C.

Original languageEnglish (US)
Pages (from-to)13-26
Number of pages14
JournalMedical Clinics of North America
Volume96
Issue number1
DOIs
StatePublished - Jan 2012

Fingerprint

LDL Cholesterol
Cholesterol
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Atherosclerotic Plaques
Vascular Diseases
Primates
Meta-Analysis
Mammals
Atherosclerosis
Newborn Infant
Guidelines
Education
Therapeutics
oxidized low density lipoprotein

Keywords

  • Atherosclerosis
  • Coronary risk
  • Low-density lipoprotein cholesterol
  • Statins

ASJC Scopus subject areas

  • Medicine(all)

Cite this

LDL Cholesterol : The Lower the Better. / Martin, Seth; Blumenthal, Roger S; Miller, Michael.

In: Medical Clinics of North America, Vol. 96, No. 1, 01.2012, p. 13-26.

Research output: Contribution to journalArticle

@article{3cdb4ce788164db48e9b59ff51ef617b,
title = "LDL Cholesterol: The Lower the Better",
abstract = "High cholesterol is often a prerequisite for atherosclerotic plaque. Low-density lipoprotein cholesterol (LDL-C) is the focus of the National Cholesterol Education Program Adult Treatment Panel guidelines. LDL-C ranges from 50 to 70 mg/dL in native hunter-gatherers, healthy human neonates, free-living primates, and other wild mammals, who are notably free of atherosclerotic vascular disease. Multiple statin trials and meta-analyses support a treatment target of LDL-C levels less than 70 mg/dL, as this is associated with improved clinical outcomes and atherosclerosis regression. In fact, no threshold has yet been identified below which patients do not benefit from lowering of LDL-C.",
keywords = "Atherosclerosis, Coronary risk, Low-density lipoprotein cholesterol, Statins",
author = "Seth Martin and Blumenthal, {Roger S} and Michael Miller",
year = "2012",
month = "1",
doi = "10.1016/j.mcna.2012.01.009",
language = "English (US)",
volume = "96",
pages = "13--26",
journal = "Medical Clinics of North America",
issn = "0025-7125",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - LDL Cholesterol

T2 - The Lower the Better

AU - Martin, Seth

AU - Blumenthal, Roger S

AU - Miller, Michael

PY - 2012/1

Y1 - 2012/1

N2 - High cholesterol is often a prerequisite for atherosclerotic plaque. Low-density lipoprotein cholesterol (LDL-C) is the focus of the National Cholesterol Education Program Adult Treatment Panel guidelines. LDL-C ranges from 50 to 70 mg/dL in native hunter-gatherers, healthy human neonates, free-living primates, and other wild mammals, who are notably free of atherosclerotic vascular disease. Multiple statin trials and meta-analyses support a treatment target of LDL-C levels less than 70 mg/dL, as this is associated with improved clinical outcomes and atherosclerosis regression. In fact, no threshold has yet been identified below which patients do not benefit from lowering of LDL-C.

AB - High cholesterol is often a prerequisite for atherosclerotic plaque. Low-density lipoprotein cholesterol (LDL-C) is the focus of the National Cholesterol Education Program Adult Treatment Panel guidelines. LDL-C ranges from 50 to 70 mg/dL in native hunter-gatherers, healthy human neonates, free-living primates, and other wild mammals, who are notably free of atherosclerotic vascular disease. Multiple statin trials and meta-analyses support a treatment target of LDL-C levels less than 70 mg/dL, as this is associated with improved clinical outcomes and atherosclerosis regression. In fact, no threshold has yet been identified below which patients do not benefit from lowering of LDL-C.

KW - Atherosclerosis

KW - Coronary risk

KW - Low-density lipoprotein cholesterol

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=84863393675&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863393675&partnerID=8YFLogxK

U2 - 10.1016/j.mcna.2012.01.009

DO - 10.1016/j.mcna.2012.01.009

M3 - Article

VL - 96

SP - 13

EP - 26

JO - Medical Clinics of North America

JF - Medical Clinics of North America

SN - 0025-7125

IS - 1

ER -